These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

918 related items for PubMed ID: 15161328

  • 21. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Hamilton A, Piccart M.
    Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
    [Abstract] [Full Text] [Related]

  • 22. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 23. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT, Robert NJ.
    MedGenMed; 2005 Aug 24; 7(3):20. PubMed ID: 16369246
    [Abstract] [Full Text] [Related]

  • 24. Aromatase inhibitors in early breast cancer therapy.
    Smith IE.
    Semin Oncol; 2004 Dec 24; 31(6 Suppl 12):9-14. PubMed ID: 15719596
    [Abstract] [Full Text] [Related]

  • 25. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE.
    Am J Clin Oncol; 2003 Aug 24; 26(4):S27-33. PubMed ID: 12902874
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C.
    Am J Clin Oncol; 2003 Aug 24; 26(4):S9-16. PubMed ID: 12902872
    [Abstract] [Full Text] [Related]

  • 28. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A.
    Cancer; 1997 Feb 15; 79(4):730-9. PubMed ID: 9024711
    [Abstract] [Full Text] [Related]

  • 29. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
    Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM.
    Cancer; 2002 Nov 01; 95(9):2006-16. PubMed ID: 12404296
    [Abstract] [Full Text] [Related]

  • 30. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
    Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M.
    Eur J Cancer; 1996 Mar 01; 32A(3):404-12. PubMed ID: 8814682
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV.
    J Clin Oncol; 1996 Jul 01; 14(7):2000-11. PubMed ID: 8683230
    [Abstract] [Full Text] [Related]

  • 34. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS, Forbes JF.
    Breast Cancer Res Treat; 2003 Jul 01; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [Abstract] [Full Text] [Related]

  • 35. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS.
    Ann Oncol; 2008 Jan 01; 19(1):16-27. PubMed ID: 17693420
    [Abstract] [Full Text] [Related]

  • 36. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R, Forbes CA, Kessels A, Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J.
    Breast Cancer Res Treat; 2010 Aug 01; 123(1):9-24. PubMed ID: 20535542
    [Abstract] [Full Text] [Related]

  • 37. Letrozole in advanced breast cancer: the PO25 trial.
    Mouridsen HT.
    Breast Cancer Res Treat; 2007 Aug 01; 105 Suppl 1(Suppl 1):19-29. PubMed ID: 17333340
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Aug 01; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 40. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
    Barnadas A, Estévez LG, Lluch-Hernández A, Rodriguez-Lescure A, Rodriguez-Sanchez C, Sanchez-Rovira P.
    Adv Ther; 2011 Dec 01; 28(12):1045-58. PubMed ID: 22068628
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 46.